Compare Stocks: EPRX, SRPT, KOD, and VCEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.58 -0.7%	$7.08	$5.16 ▼ $9.32	$561.76M	1.07	482,311 shs	781,667 shs
KOD Kodiak Sciences	$33.80 +4.3%	$38.89	$10.94 ▼ $47.84	$2.04B	2.18	642,205 shs	1.04 million shs
SRPT Sarepta Therapeutics	$20.81 +3.3%	$18.71	$14.68 ▼ $25.32	$2.13B	0.27	3.19 million shs	2.19 million shs
VCEL Vericel	$40.22 +1.7%	$43.03	$28.95 ▼ $49.32	$2.03B	1.04	478,082 shs	546,954 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+0.70%	+7.06%	+28.38%	+35.21%	+44.97%
KOD Kodiak Sciences	-0.89%	-2.17%	-15.42%	-12.50%	+240.19%
SRPT Sarepta Therapeutics	+0.15%	-3.73%	+7.18%	+16.69%	+15.55%
VCEL Vericel	-1.17%	-0.13%	-7.33%	-2.08%	+24.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.58 -0.7%	$7.08	$5.16 ▼ $9.32	$561.76M	1.07	482,311 shs	781,667 shs
KOD Kodiak Sciences	$33.80 +4.3%	$38.89	$10.94 ▼ $47.84	$2.04B	2.18	642,205 shs	1.04 million shs
SRPT Sarepta Therapeutics	$20.81 +3.3%	$18.71	$14.68 ▼ $25.32	$2.13B	0.27	3.19 million shs	2.19 million shs
VCEL Vericel	$40.22 +1.7%	$43.03	$28.95 ▼ $49.32	$2.03B	1.04	478,082 shs	546,954 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+0.70%	+7.06%	+28.38%	+35.21%	+44.97%
KOD Kodiak Sciences	-0.89%	-2.17%	-15.42%	-12.50%	+240.19%
SRPT Sarepta Therapeutics	+0.15%	-3.73%	+7.18%	+16.69%	+15.55%
VCEL Vericel	-1.17%	-0.13%	-7.33%	-2.08%	+24.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	109.79% Upside
KOD Kodiak Sciences	2.57	Moderate Buy	$53.67	58.78% Upside
SRPT Sarepta Therapeutics	2.11	Hold	$24.07	15.65% Upside
VCEL Vericel	2.67	Moderate Buy	$58.40	45.20% Upside

Current Analyst Ratings Breakdown

Latest EPRX, SRPT, KOD, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
9/9/2026	SRPT Sarepta Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/8/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/5/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00
7/31/2026	VCEL Vericel	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
7/31/2026	VCEL Vericel	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $58.00
7/31/2026	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$54.00 ➝ $58.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
SRPT Sarepta Therapeutics	$2.20B	1.00	N/A	N/A	$10.89 per share	1.91
VCEL Vericel	$276.26M	7.46	$0.56 per share	71.20	$7.01 per share	5.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.43	0.29	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	85.58	47.88	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest EPRX, SRPT, KOD, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
KOD Kodiak Sciences	N/A	2.49	2.49
SRPT Sarepta Therapeutics	0.55	4.42	2.62
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KOD Kodiak Sciences	89.06%
SRPT Sarepta Therapeutics	86.68%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KOD Kodiak Sciences	44.40%
SRPT Sarepta Therapeutics	6.90%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

EPRX, SRPT, KOD, and VCEL Headlines

Recent News About These Companies

Bank of America Corp DE Invests $45.21 Million in Vericel Corporation $VCEL

September 22 at 3:04 AM | marketbeat.com

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14, 2026 | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 64,404 Vericel Corporation $VCEL

August 27, 2026 | marketbeat.com

EFG International AG Purchases Shares of 127,642 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 8,092,226 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

398,365 Shares in Vericel Corporation $VCEL Bought by Osterweis Capital Management Inc.

August 25, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares

August 1, 2026 | insidertrades.com

Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EPRX, SRPT, KOD, and VCEL Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.58 -0.06 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$8.65 +0.07 (+0.82%)

As of 07:46 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Kodiak Sciences NASDAQ:KOD

$33.80 +1.38 (+4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$33.61 -0.19 (-0.56%)

As of 07:59 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Sarepta Therapeutics NASDAQ:SRPT

$20.81 +0.67 (+3.33%)

Closing price 04:00 PM Eastern

Extended Trading

$21.14 +0.33 (+1.56%)

As of 07:52 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$40.22 +0.67 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$40.22 0.00 (0.00%)

As of 07:30 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, SRPT, KOD, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, SRPT, KOD, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, SRPT, KOD, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EPRX, SRPT, KOD, and VCEL Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Kodiak Sciences NASDAQ:KOD

Sarepta Therapeutics NASDAQ:SRPT

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, SRPT, KOD, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, SRPT, KOD, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, SRPT, KOD, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EPRX, SRPT, KOD, and VCEL Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Kodiak Sciences NASDAQ:KOD

Sarepta Therapeutics NASDAQ:SRPT

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools